It was shown that individuals with elevated levels of FERMT1 respond more to Palbociclib (CDK4/6 inhibitor), TAE-226 (focal adhesion kinase selective inhibitor), and AM-5992 (AMG-925; dual inhibitor of CDK4 and FLT3), which can be combined in combination therapy to enhance the treatment of pancreatic cancer [183]. The gene discussed is CDK4; the disease is familial pancreatic carcinoma.